ARCHIVES

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

House Bill, Report Do Not Include Any Earmarks Or Directives To Aid CCOP, Centers, Cancer Control

August 7, 1987

Minorities Increasingly Involved In Research, Training Programs

December 5, 1986

NCI Plans a Catalog Of Research Tools

April 30, 1999

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

July 4, 1997

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Anti-NCI Forces Fail to Raid $70 Million from Cancer Program

September 26, 1975